Success Metrics

Clinical Success Rate
92.9%

Based on 13 completed trials

Completion Rate
93%(13/14)
Active Trials
5(22%)
Results Posted
46%(6 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_4
3
13%
Ph not_applicable
1
4%
Ph phase_3
12
52%
Ph phase_2
1
4%
Ph phase_1
3
13%

Phase Distribution

3

Early Stage

1

Mid Stage

15

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
3(15.0%)
Phase 2Efficacy & side effects
1(5.0%)
Phase 3Large-scale testing
12(60.0%)
Phase 4Post-market surveillance
3(15.0%)
N/ANon-phased studies
1(5.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.7%

13 of 15 finished

Non-Completion Rate

13.3%

2 ended early

Currently Active

5

trials recruiting

Total Trials

23

all time

Status Distribution
Active(8)
Completed(13)
Terminated(2)

Detailed Status

Completed13
Recruiting4
Not yet recruiting2
Withdrawn1
Enrolling by invitation1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
5
Success Rate
92.9%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (15.0%)
Phase 21 (5.0%)
Phase 312 (60.0%)
Phase 43 (15.0%)
N/A1 (5.0%)

Trials by Status

not_yet_recruiting29%
recruiting417%
withdrawn14%
enrolling_by_invitation14%
active_not_recruiting14%
completed1357%
terminated14%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT05164172Phase 3

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Recruiting
NCT07035197

Facilitators and Barriers to Eptinezumab Administration in Thailand

Completed
NCT04965675Phase 3

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Recruiting
NCT05897320Phase 3

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Recruiting
NCT06701526Phase 4

A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

Active Not Recruiting
NCT05452239Phase 4

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Completed
NCT05334927

China HeadAche DIsorders RegiStry

Recruiting
NCT04921384Phase 3

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

Completed
NCT05064371Phase 3

Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

Completed
NCT07191145Phase 3

Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)

Not Yet Recruiting
NCT06212661

Migraine Medication Effects on Urinary Symptoms

Enrolling By Invitation
NCT05937152Phase 2

A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

Withdrawn
NCT04688775Phase 3

Eptinezumab in Participants With Episodic Cluster Headache

Completed
NCT05064397Phase 3

A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

Completed
NCT05284019Phase 4

Real World Effectiveness of Eptinezumab in Participants With Migraine

Terminated
NCT06428838Phase 3

Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

Not Yet Recruiting
NCT05635604Not Applicable

Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

Completed
NCT04537429Phase 1

A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

Completed
NCT04418765Phase 3

A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments

Completed
NCT04772742Phase 3

Eptinezumab in Adults With Migraine and Medication Overuse Headache

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23